selected scholarly activity
-
chapters
- Lung Carcinoma Surveillance Counterpoint: Canada. 83-92. 2013
- The cost and cost-effectiveness of lung cancer management. 247-263. 2008
- CEA: A Useful Prognostic Marker in Small Cell Lung Cancer. 691-693. 1985
- NON-SMALL-CELL LUNG CANCER: BLEOMYCIN PLUS ETOPOSIDE AND CISPLATIN. 215-224. 1985
-
conferences
- Evaluating the Economic Burden of Acute Myeloid Leukemia in Canada. Acta Haematologica. 1-13. 2024
- Integrating Smoking Cessation Into Low-Dose Computed Tomography Lung Cancer Screening: Results of the Ontario, Canada Pilot. Journal of Thoracic Oncology. 1323-1333. 2023
- Reporting of Tobacco Use and Impact on Outcomes in Cancer Cooperative Group Clinical Trials: A Systematic Scoping Review. Journal of Thoracic Oncology. S123-S124. 2021
- The impact of tobacco retail density on overall survival (OS) in lung cancer survivors.. Journal of Clinical Oncology. 2020
- ES20.03 Tobacco Control Integration in Cancer Care: The Canadian Experience. Journal of Thoracic Oncology. S62-S62. 2019
- Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model. Annals of Oncology. 2019
- OA09.07 Implementing an Opt-Out Approach to Smoking Cessation Referrals for Cancer Patients in Ontario, Canada. Journal of Thoracic Oncology. S230-S231. 2019
- Tobacco retail access and tobacco cessation among head and neck cancer (HNC) survivors. Annals of Oncology. 742-742. 2019
- Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors.. Journal of Clinical Oncology. 2019
- Cancer patient (pt) attitudes and preferences towards smoking status assessment.. Journal of Clinical Oncology. 177-177. 2018
- A systematic approach to smoking cessation in regional cancer centres in Ontario, Canada. Annals of Oncology. viii627-viii627. 2018
- Awareness of the cancer and non-cancer related harms of continued smoking in cancer survivors. Annals of Oncology. viii605-viii605. 2018
- How advanced lung cancer patients are really treated at the population level? The Ontario, Canada experience. Annals of Oncology. viii568-viii568. 2018
- MA18.02 The Impact of Treatment Evolution in NSCLC (iTEN) Model: Development and Validation. Journal of Thoracic Oncology. S418-S419. 2018
- MA18.03 How in the Real World Are Lung Cancer Patients Treated? The Ontario, Canada Experience. Journal of Thoracic Oncology. S419-S419. 2018
- MA18.07 Awareness of the Harms of Continued Smoking Among Lung Cancer (LC) Survivors. Journal of Thoracic Oncology. S420-S420. 2018
- OA09.01 5As to 3As: Evolution of the Systematic Approach to Smoking Cessation in Ontario’s Regional Cancer Centres. Journal of Thoracic Oncology. S340-S340. 2018
- OA09.02 Acceptance of Smoking Cessation Services in Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk. Journal of Thoracic Oncology. S341-S341. 2018
- P1.15-27 Patient Characteristics, Treatment Patterns and Survival for Unresectable Stage III NSCLC in Ontario, Canada. Journal of Thoracic Oncology. S623-S623. 2018
- P1.15-28 Real World Treatment Patterns and Survival of Stage IV Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada. Journal of Thoracic Oncology. S624-S624. 2018
- P2.10-02 Variations in Smoking Cessation Activities at Ontario’s Regional Cancer Centres. Journal of Thoracic Oncology. S773-S774. 2018
- P2.15-09 The Impact of Treatment Evolution in NSCLC (iTEN) Model: Survival and Cost of Treating Patients with Advanced NSCLC in 2017. Journal of Thoracic Oncology. S820-S820. 2018
- PCN210 - USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF A 5-YEAR NON-SMALL CELL LUNG CANCER COHORT. Value in Health. S49-S50. 2018
- PCN221 - STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER TREATMENT PATTERNS AND COSTS: AN ONTARIO, CANADA ANALYSIS. Value in Health. S51-S52. 2018
- Cancer patient attitudes and preferences towards smoking status assessment.. Journal of Clinical Oncology. 110-110. 2018
- MA 18.01 Driving Improvements in Cancer Care Ontario's Smoking Cessation Initiative for Cancer Patients in Ontario, Canada. Journal of Thoracic Oncology. S1877-S1877. 2017
- OA 06.01 Costs and Cost-Effectiveness of Smoking Cessation Within an Organized CT Lung Cancer (LC) Screening Program. Journal of Thoracic Oncology. S1757-S1758. 2017
- OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model – the Pan-Canadian Study. Journal of Thoracic Oncology. S1784-S1785. 2017
- OA17.02 Potential Health and Economic Consequences of Organized vs Opportunistic Lung Cancer Screening in Canada. Journal of Thoracic Oncology. S309-S309. 2017
- P1.05-068 Elderly Patients with Resected Stage II Non-small Cell Lung Cancer Are Less Likely to Have a Consultation with a Medical Oncologist. Journal of Thoracic Oncology. S657-S657. 2017
- P3.07-016 Ontario's Episode-Based Funding Model Reveals Practice Variation in Adjuvant NSCLC Chemotherapy. Journal of Thoracic Oncology. S1440-S1440. 2017
- Assessing the quality of chemotherapy in an episode-based funding model in Ontario. Journal of Clinical Oncology. 2016
- Cost Efficacy of Tobacco Cessation Versus Treatment of Lung Cancer. Journal of Thoracic Oncology. S131-S132. 2015
- Introducing Smoking Cessation Across Ontario's Cancer Treatment System: Early Successes and Continuing Challenges. Journal of Thoracic Oncology. S190-S190. 2015
- The Cancer Risk Management Model: A Tool to Inform Canadian Policymakers Implementing Low-Dose CT Screening for Lung Cancer. Journal of Thoracic Oncology. S192-S192. 2015
- Role of treatment in international differences in one-year mortality from early stage non-small cell lung cancer: a tentative answer from the International Cancer Benchmarking Partnership study. European Journal of Cancer Care. 59-59. 2015
- ACCELERATING DECISION-MAKING WITH MICROSIMULATION: THE ADOPTION OF EVIDENCE IN CERVICAL CANCER SCREENING. Asia-Pacific Journal of Clinical Oncology. 5-5. 2014
- First Two Years of Health System Resources and Costs Following a Stage Defined Breast Cancer Diagnosis: A Population Based Approach. Value in Health. A97-A97. 2014
- BIENNIAL LUNG CANCER SCREENING BY LOW-DOSE CT SCAN - A SIMULATION OF COST EFFECTIVENESS IN CANADA. Journal of Thoracic Oncology. S149-S149. 2013
- IMPLEMENTING DYSPNEA MANAGEMENT: A QUALITY IMPROVEMENT PROJECT FOR PATIENTS WITH LUNG CANCER IN ONTARIO, CANADA. Journal of Thoracic Oncology. S1010-S1010. 2013
- Population Based Utilization of Radiation Therapy by a Canadian Breast Cancer Cohort. Value in Health. A430-A430. 2013
- RESOURCE CONSTRAINTS AS A BARRIER TO LUNG CANCER MANAGEMENT: DEVELOPED NATIONS. Journal of Thoracic Oncology. S74-S74. 2013
- VARIATION IN THE UPTAKE OF THE COMBINED MODALITY PRACTICE GUIDELINE FOR SURGICALLY UNRESECTABLE STAGE III NSCLC IN ONTARIO. Journal of Thoracic Oncology. S853-S854. 2013
- VARIATIONS IN THE UPTAKE OF PRACTICE GUIDELINE RECOMMENDATIONS ON ADJUVANT CHEMOTHERAPY USE FOLLOWING SURGICAL RESECTION IN ONTARIO. Journal of Thoracic Oncology. S1217-S1218. 2013
- Homecare utilization and costs in stage IV lung cancer: a Canadian public payer experience. European Journal of Cancer. S327-S328. 2013
- Cancer Care Ontario's lung disease pathway initiative: Building resources for lung cancer quality care. Journal of Clinical Oncology. 2013
- Simulating the cost-effectiveness of lung cancer screening by low-dose CT scan in Canada. Journal of Clinical Oncology. 2013
- Lung Cancer Disease Pathway Management Initiative: A Novel Approach to Provincial Quality Improvement. International Journal of Radiation Oncology Biology Physics. S542-S542. 2012
- Cancer Care Ontario's Lung Cancer Disease Pathway Management Initiative: A Novel Approach to Provincial Quality Improvement. Journal of Thoracic Oncology. S272-S273. 2012
- Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study.. Journal of Clinical Oncology. 2012
- Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL). Blood. 907-908. 2011
- An Ontario Clinical Oncology (OCOG) Randomized Trial (PET START) of FDG PET/CT in Stage 3 Non-small Cell Lung Cancer (NSCLC): Impact of PET on Survival. International Journal of Radiation Oncology Biology Physics. S137-S137. 2011
- AN ONTARIO CLINICAL ONCOLOGY GROUP (OCOG) RANDOMIZED TRIAL (PET START) OF FDG PET/CT IN PATIENTS WITH STAGE 3 NON-SMALL CELL LUNG CANCER (NSCLC): IMPACT OF PET ON RADIATION TREATMENT VOLUMES. Journal of Thoracic Oncology. S428-S428. 2011
- CRITICAL PERSPECTIVE ON THE TREATMENT OF STAGE IV NON-SMALL CELL LUNG CANCER: COST ANALYSIS OF NEW DRUGS. Journal of Thoracic Oncology. S209-S210. 2011
- LUNG CANCER DISEASE PATHWAY MANAGEMENT IN ONTARIO, CANADA. Journal of Thoracic Oncology. S1415-S1415. 2011
- LUNG CANCER SCREENING BY LOW DOSE CT (DISCUSSANT). Journal of Thoracic Oncology. S132-S134. 2011
- An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.. Journal of Clinical Oncology. 2011
- Canadian cancer risk management model: A new health policy tool useful in policy decisions related to lung cancer.. Journal of Clinical Oncology. e16541-e16541. 2011
- Impact of increased use of adjuvant chemotherapy in non-small cell lung cancer: A population and economic assessment.. Journal of Clinical Oncology. e16630-e16630. 2011
- Population-based health care cost estimates related to breast cancer by staging.. Journal of Clinical Oncology. 6108-6108. 2011
- 30 PET START: THE FIRST RANDOMIZED CLINICAL TRIAL EVALUATING THE IMPACT OF POSITRON EMISSION TOMOGRAPHY IN STAGE III NON-SMALL CELL LUNG CANCER. Radiotherapy and Oncology. S10-S10. 2009
- 87 DEVELOPING CONSENSUS AMONG CLINICAL EXPERTS AND NONEXPERTS FOR THE ROLE OF POSITRON EMISSION TOMOGRAPHY IN SMALL CELL LUNG CANCER. Radiotherapy and Oncology. S28-S28. 2009
- Management change as a result of positron emission tomography (PET) in a prospective randomized clinical trial. Journal of Thoracic Oncology. S746-S746. 2009
- Molecular Targeted Therapy - Can We Afford it?. Journal of Thoracic Oncology. S211-S212. 2009
- Positron emission tomography in small cell lung cancer: a systematic review and practice guideline in Ontario, Canada. Journal of Thoracic Oncology. S462-S462. 2009
- Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document. Journal of Clinical Oncology. 2009
- Impact of positron emission tomography (PET) in stage III non-small cell lung cancer (NSCLC): A prospective randomized trial (PET START). Journal of Clinical Oncology. 2009
- Integration between primary care providers and the cancer system: Gaps and opportunities. Journal of Clinical Oncology. 2009
- PET-CT compared to invasive mediastinal staging in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2009
- HT2 HEALTH TECHNOLOGY ASSESSMENT – A COMPREHENSIVE FRAMEWORK FOR EVIDENCE-BASED RECOMMENDATIONS IN ONTARIO. Value in Health. A11-A11. 2009
- INTEGRATING FAMILY PHYSICIANS INTO CANCER CARE. Radiotherapy and Oncology. S26-S27. 2008
- A randomized controlled trial (RCT) of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus conventional imaging (CI) in staging potentially resectable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 7502-7502. 2008
- Impact of clinical and molecular predictors of benefit from erlotinib in advanced non-small cell lung cancer on cost-effectiveness. Journal of Clinical Oncology. 6531-6531. 2008
- PCN58 A COST UTILITY ANALYSIS OF ERLOTINIB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). Value in Health. A72-A72. 2008
- PCN93 THREE SCIENTIFIC PARADIGMS IN HEALTH TECHNOLOGY ASSESSMENT: EXPERIENCES OF THE COMMITTEE TO EVALUATE DRUGS IN ONTARIO, CANADA. Value in Health. A82-A82. 2008
- Determining knowledge transfer gaps in the life cycle of evidence for chemotherapy in non-small cell lung cancer (NSCLC) through cumulative meta-analysis. Journal of Clinical Oncology. 2007
- E22. Reimbursement policies, research andprescribing practices: The Canadian perspective. Lung Cancer. S36-S37. 2005
- The role of high dose rate endobronchial brachytherapy in the palliation of patients with non-small cell lung cancer: a practice-guideline. Radiotherapy and Oncology. S131-S132. 2004
- Neovastat (Æ-941) in addition to combined modality therapy for locally-advanced unresectable non-small cell lung cancer (NSCLC):: An NCI-sponsored multicenter phase III study.. Clinical Cancer Research. 3659S-3659S. 2001
- Æ-941, an inhibitor of angiogenesis:: Rationale for a phase III study on Æ-941 in combination with induction chemotherapy/radiotherapy in patients with non small cell lung cancer (NSCLC).. Clinical Cancer Research. 3774S-3774S. 1999
- New insights into the cost-effectiveness of lung cancer treatment. Oncology. 16-21. 1999
- Opportunities to reduce the cost of care for breast cancer (BC) in Canada. European Journal of Cancer. PP20-PP20. 1997
- Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.. Seminars in Oncology. S7-56-S7-63. 1997
- Concurrent daily chemotherapy with hyperfractionated thoracic irradiation in stage IIIA&B NSCLC. European Journal of Cancer. 1100-1100. 1995
- The health economics of lung cancer and an estimate of the cost effectiveness of single agent gemcitabine in stage IV NSCLC. European Journal of Cancer. 1057-1057. 1995
- CURRENT PERSPECTIVES IN THE TREATMENT OF NONSMALL CELL LUNG-CANCER - DISCUSSION. LUNG CANCER VOL 9, SUPPL NO 2 (1993). S117-S120. 1993
- A PHASE-II STUDY OF IFOSFAMIDE, CISPLATIN, ETOPOSIDE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER - A PRELIMINARY-REPORT. Seminars in Oncology. 19-23. 1990
- The value of nutritional support in the cancer patient. Canadian Journal of Gastroenterology. 1990
- SUPPORTIVE CARE FOR PATIENTS WITH SMALL-CELL LUNG-CANCER (REPRINTED FROM LUNG-CANCER, VOL 5/4-6, 1989). MANAGEMENT OF SMALL CELL LUNG CANCER. 201-206. 1989
- THE ROLE OF THORACIC RADIATION-THERAPY IN SMALL-CELL CARCINOMA OF THE LUNG - A CONCENSUS REPORT (REPRINTED FROM LUNG-CANCER, VOL 5/4-6, 1989). MANAGEMENT OF SMALL CELL LUNG CANCER. 17-20. 1989
- HIGH-DOSE EPIRUBICIN (E) GIVEN AS A DAILY X 3 SCHEDULE IN PATIENTS (PTS) WITH UNTREATED EXTENSIVE NON-SMALL CELL LUNG-CANCER (NSCLC) - A PHASE-I-II STUDY. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 208-208. 1988
- PERTURBATIONS IN PLASMA AMINO-ACID PROFILES IN SMALL CELL LUNG-CANCER (SCLC) AND THEIR RESPONSE TO TREATMENT. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 18-18. 1988
- A RANDOMIZED STUDY OF STANDARD OR AUGMENTED ORAL NUTRITIONAL SUPPORT VERSUS ADLIB NUTRITIONAL INTAKE IN PATIENTS WITH ADVANCED COLORECTAL AND NON-SMALL CELL LUNG-CANCER. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 209-209. 1986
- SMALL CELL-CARCINOMA OF THE LUNG - DERIVATION OF A PROGNOSTIC INDEX. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 189-189. 1986
- THE COMBINED USE OF LDH AND CEA AS INDEPENDENT PROGNOSTIC MARKERS FOR SMALL-CELL LUNG-CANCER (SCLC). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 162-162. 1986
- CEA - A USEFUL PROGNOSTIC MARKER FOR SMALL CELL LUNG-CANCER (SCLC). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 158-158. 1984
- PHASE-II EVALUATION OF BISANTRENE IN ADVANCED RENAL-CELL CARCINOMA (RCC) USING A WEEKLY X-3 SCHEDULE. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 180-180. 1984
- CHANGES IN SUBSTRATE-HORMONE PROFILES AND AMINO-ACID-METABOLISM IN SMALL CELL LUNG-CANCER (SCLC). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 164-164. 1983
- MYASTHENIC SYNDROME OF EATON-LAMBERT - RESPONSE TO THERAPY OF SMALL CELL-CANCER OF THE LUNG. Canadian Journal of Neurological Sciences. 140-140. 1983
- PROGNOSTIC FACTORS IN PATIENTS WITH SMALL CELL-CARCINOMA OF THE LUNG (SCCL). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 145-145. 1983
- THE IMPACT OF INCREASED EMERGENCY PREPAREDNESS REQUIREMENTS ON THE TVA TRAINING-PROGRAM FOR RADIOLOGICAL EMERGENCY RESPONSE. Health Physics. 134-134. 1982
- ADRIAMYCIN CARDIOTOXICITY - CORRELATION OF RADIONUCLIDE ANGIOGRAPHY AND PATHOLOGY. Australian and New Zealand Journal of Medicine. 580-580. 1981
- COMBINED MODALITY INDUCTION THERAPY WITHOUT MAINTENANCE CHEMOTHERAPY FOR SMALL CELL-CARCINOMA OF LUNG (SCCL). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 494-494. 1981
- COMPUTED-TOMOGRAPHY (CT) OF BRAIN, LIVER AND UPPER ABDOMEN IN THE STAGING OF SMALL CELL-CARCINOMA OF THE LUNG (SCCL). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 494-494. 1981
- GATED RADIONUCLIDE ANGIOGRAPHY (GNA) AND ENDOMYOCARDIAL BIOPSY (EMB) IN THE ASSESSMENT OF DOXORUPICIN CARDIOTOXICITY (DCT). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 334-334. 1981
- HYPERALIMENTATION (IVH) AS AN ADJUNCT TO THERAPY FOR SMALL CELL LUNG-CANCER (SCCL) - PRELIMINARY-REPORT ON SAFETY AND NUTRITIONAL EFFICACY. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 421-421. 1981
- PROGNOSTIC VALUE OF PLASMA CARCINOEMBRYONIC (CEA) DETERMINATIONS IN SMALL-CELL LUNG-CANCER (SCLC). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 185-185. 1981
- UPPER HALF BODY IRRADIATION (UHBI) AS CONSOLIDATION THERAPY FOR EXTENSIVE SMALL CELL-CARCINOMA OF LUNG (SCCL). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 411-411. 1981
-
journal articles
- Exploring cannabis information and perceptions of cannabis harms among patients with cancer.. Journal of Clinical Oncology. 20:361-361. 2024
- Risk-based lung cancer screening performance in a universal healthcare setting. Nature Medicine. 30:1054-1064. 2024
- Physician-brief advice for promoting smoking cessation among cancer patients on treatment in low and middle-income countries: a scoping review. BMC Cancer. 24:149. 2024
- Integrating Smoking Cessation Into Low-Dose Computed Tomography Lung Cancer Screening: Results of the Ontario, Canada Pilot. Journal of Thoracic Oncology. 18:1323-1333. 2023
- Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. ESMO Open. 7:100605-100605. 2022
- Breathing Life Into Lung Cancer Screening Trials. Journal of Thoracic Oncology. 17:1244-1246. 2022
- Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned. Current Oncology. 29:5616-5626. 2022
- Ignoring the Obvious: Smoking Cessation Improves Survival. Journal of Thoracic Oncology. 17:596-598. 2022
- Smoking cessation: health system challenges and opportunities. Tobacco Control. 31:340-347. 2022
- Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise. Current Oncology. 28:4645-4654. 2021
- Reporting of tobacco use and impact on outcomes in cancer cooperative group clinical trials: A systematic scoping review.. Journal of Clinical Oncology. 39:40-40. 2021
- Critical Determinants of Cancer Treatment Outcomes: Smoking Must Be Addressed at the Highest Levels in Cancer Care. Journal of Thoracic Oncology. 16:891-893. 2021
- OA10.03 Reporting of Tobacco Use and Impact on Outcomes in Cancer Cooperative Group Clinical Trials: A Systematic Scoping Review. Journal of Thoracic Oncology. 16:S123-S124. 2021
- Identifying Best Implementation Practices for Smoking Cessation in Complex Cancer Settings. Current Oncology. 28:471-484. 2021
- A reply to “Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model”. Lung Cancer. 151:110-111. 2021
- Real-World Treatment Patterns and Survival in Stage IV Non-Small-Cell Lung Cancer in Canada. Current Oncology. 27:361-367. 2020
- Retrospective Cohort Study of Unresectable Stage III Non-Small-Cell Lung Cancer in Canada. Current Oncology. 27:354-360. 2020
- Awareness of the Harms of Continued Smoking Among Cancer Survivors. Supportive Care in Cancer. 28:3409-3419. 2020
- Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model. CMAJ open. 8:E585-E592. 2020
- Smoking Cessation in Cancer Care: Myths, Presumptions and Implications for Practice. Clinical Oncology. 32:400-406. 2020
- The impact of tobacco retail density on overall survival (OS) in lung cancer survivors.. Journal of Clinical Oncology. 38:12058-12058. 2020
- Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. BMJ Open. 10:e032884-e032884. 2020
- Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. Lung Cancer. 139:185-194. 2020
- Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. CMAJ open. 8:E191-E198. 2020
- Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model. Annals of Oncology. 30:v651-v652. 2019
- P1.10-05 Tobacco Retail Availability and Tobacco Cessation Among Lung Cancer Survivors. Journal of Thoracic Oncology. 14:S512-S512. 2019
- The Generation of Two Specific Cancer Costing Algorithms Using Ontario Administrative Databases. Current Oncology. 26:682-692. 2019
- Tobacco retail access and tobacco cessation among head and neck cancer (HNC) survivors. Annals of Oncology. 30:v742-v742. 2019
- Impact of smoking on health system costs among cancer patients in a retrospective cohort study in Ontario, Canada. BMJ Open. 9:e026022-e026022. 2019
- Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors.. Journal of Clinical Oncology. 37:11559-11559. 2019
- Implementing smoking cessation within cancer treatment centres and potential economic impacts. Translational Lung Cancer Research. 8:S11-S20. 2019
- Cost-of-Illness Study for Non-Small-Cell Lung Cancer Using Real-World Data. Current Oncology. 26:102-107. 2019
- Sociodemographic characteristics associated with thyroid cancer risk in Canada.. Health Reports. 29:3-11. 2018
- Cost-Effectiveness of Smoking Cessation Within a Lung Cancer Screening Program in Canada. Journal of Global Oncology. 4:41s-41s. 2018
- Lung Cancer–Related Clinical and Economic Impacts of Achieving a 5% Smoking Prevalence Rate by 2035 in Canada. Journal of Global Oncology. 4:28s-28s. 2018
- The OncoSim Cancer Simulation Platform: A Tool to Project the Population Effects of Cancer Control Interventions in Canada. Journal of Global Oncology. 4:77s-77s. 2018
- Economic evaluation of smoking cessation in Ontario's regional cancer programs. Cancer Medicine. 7:4765-4772. 2018
- How Equitable is Access to Treatment for Lung Cancer Patients? A Population-Based Review of Treatment Practices in Ontario. Lung Cancer Management. 6:77-86. 2017
- The OncoSim Model: Development and Use for Better Decision-Making in Canadian Cancer Control. Current Oncology. 24:401-406. 2017
- OA 14.03 Ontario's Bundled Payment System for Systemic Therapy Supports Lung Cancer Trials. Journal of Thoracic Oncology. 12:S1782-S1783. 2017
- Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. The Lancet Oncology. 18:1523-1531. 2017
- Evaluating Cost-Effectiveness: An Essential Part of New Cancer Drug Approvals. Journal of Thoracic Oncology. 12:1461-1463. 2017
- The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. Journal of Thoracic Oncology. 12:1210-1222. 2017
- Measuring value and benefit—a matter of perspective. The Lancet Oncology. 18:839-840. 2017
- Lessons Learned Implementing a Province-Wide Smoking Cessation Initiative in Ontario’s Cancer Centres. Current Oncology. 24:185-190. 2017
- Engaging specialist oncologists in the assessment of oncology drugs in Canada. The Lancet Oncology. 18:573-575. 2017
- Clinical trials in Ontario’s quality-based funding model.. Journal of Clinical Oncology. 35:186-186. 2017
- Towards Integrating Primary Care with Cancer Care: A Regional Study of Current Gaps and Opportunities in Canada. Healthcare Policy. 12:50-65. 2017
- P1.05-067 Consultation with Medical Oncology Less Common in Elderly Patients with Resected Stage II Nonsmall Cell Lung Cancer. Journal of Thoracic Oncology. 12:S656-S657. 2017
- Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness. Lung Cancer. 101:98-103. 2016
- Using Data From Ontario’s Episode-Based Funding Model to Assess Quality of Chemotherapy. JCO Oncology Practice. 12:e870-e877. 2016
- Implementing Low-Dose Computed Tomography Screening for Lung Cancer in Canada: Implications of Alternative At-Risk Populations, Screening Frequency, and Duration. Current Oncology. 23:179-187. 2016
- Assessing the quality of chemotherapy in an episode-based funding model in Ontario.. Journal of Clinical Oncology. 34:2-2. 2016
- Clarifying Assumptions and Outcomes in Cost-Effectiveness Analyses—Reply. JAMA Oncology. 2:278-278. 2016
- Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?. ESMO Open. 1:e000124-e000124. 2016
- A Population-Based Study of the Epidemiology of Pancreatic Cancer: A Brief Report. Current Oncology. 22:478-484. 2015
- Cost-effectiveness of Lung Cancer Screening in Canada. JAMA Oncology. 1:807-807. 2015
- Eligibility for low-dose computerized tomography screening among asbestos-exposed individuals. Scandinavian Journal of Work, Environment and Health. 41:407-412. 2015
- Evaluation of the natural history of cancer of the cervix, implications for prevention. The Cancer Risk Management Model (CRMM) – Human papillomavirus and cervical components. Journal of Cancer Policy. 4:1-6. 2015
- A systematic approach to smoking cessation in Ontario’s Regional Cancer Programs.. Journal of Clinical Oncology. 33:6544-6544. 2015
- Performance of the cancer risk management model lung cancer screening module. Health Reports. 26:11-18. 2015
- A mixed methods approach to understand variation in lung cancer practice and the role of guidelines. Implementation Science. 9:36. 2014
- Health System Costs for Stage-Specific Breast Cancer: A Population-Based Approach. Current Oncology. 21:281-293. 2014
- Home Care Utilization and Costs in Stage IV Lung Cancer: a Canadian Public Payer Experience. Lung Cancer Management. 3:439-442. 2014
- Measuring alignment with evidence-informed practice in Ontario’s systemic treatment funding model.. Journal of Clinical Oncology. 32:15-15. 2014
- Implementing a Regional Oncology Information System: Approach and Lessons Learned. Current Oncology. 21:224-233. 2014
- Population-Based Utilization of Radiation Therapy by a Canadian Breast Cancer Cohort. Current Oncology. 21:715-717. 2014
- Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada. Journal of Thoracic Oncology. 9:1449-1458. 2014
- International Efforts in Health Care Reform: Systemic Treatment Funding Model Reform in Ontario. JCO Oncology Practice. 10:190-192. 2014
- End-of-life home care utilization and costs in patients with advanced colorectal cancer. Journal of Community and Supportive Oncology. 12:92-98. 2014
- Utilization and costs of home care for patients with colorectal cancer: a population-based study. CMAJ open. 2:E11-E17. 2014
- Accelerated care versus standard care among patients with hip fracture: the HIP ATTACK pilot trial. CANADIAN MEDICAL ASSOCIATION JOURNAL. 186:E52-E60. 2014
- Clinical Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Staging of Patients with Potentially Resectable Esophageal Cancer. Journal of Thoracic Oncology. 8:1563-1569. 2013
- Raising the Bar: Using Program Evaluation for Quality Improvement. Healthcare Management Forum. 26:191-195. 2013
- Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). Lung Cancer. 82:115-120. 2013
- Improving the Quality of Lung Cancer Care in Ontario: The Lung Cancer Disease Pathway Initiative. Journal of Thoracic Oncology. 8:876-882. 2013
- Cancer Care Ontario’s lung disease pathway initiative: Building resources for lung cancer quality care.. Journal of Clinical Oncology. 31:e17531-e17531. 2013
- Simulating the cost-effectiveness of lung cancer screening by low-dose CT scan in Canada.. Journal of Clinical Oncology. 31:6550-6550. 2013
- Prognostic Implications of Treatment Delays in the Surgical Resection of Lung Cancer. Thoracic Surgery Clinics. 23:225-232. 2013
- CANADIAN CANCER RISK MANAGEMENT MODEL: EVALUATION OF CANCER CONTROL. International Journal of Technology Assessment in Health Care. 29:131-139. 2013
- A Ten-Year History: The Cancer Quality Council of Ontario. Healthcare Quarterly. 15:24-27. 2012
- Population-Based Home Care Services in Breast Cancer: Utilization and Costs. Current Oncology. 19:383-391. 2012
- Using a disease pathway management (DPM) approach to improve the quality of lung cancer care in Ontario.. Journal of Clinical Oncology. 30:93-93. 2012
- The Evaluation of Cancer Control Interventions in Lung Cancer using the Canadian Cancer Risk Management Model. Lung Cancer Management. 1:25-33. 2012
- Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study.. Journal of Clinical Oncology. 30:6049-6049. 2012
- Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. Value in Health. 15:580-585. 2012
- In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival. Health Affairs. 31:709-717. 2012
- Variation and Consternation: Access to Unfunded Cancer Drugs in Canada. JCO Oncology Practice. 8:35-39. 2012
- Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL). Blood. 118:2068-2068. 2011
- Computed Tomography Screening for Lung Cancer without a Smoking Cessation Program—Not a Cost-Effective Idea. Journal of Thoracic Oncology. 6:1781-1783. 2011
- Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial. Journal of Thoracic Oncology. 6:1367-1372. 2011
- Enhancing Patient Flow in an Acute Care Hospital: Successful Strategies at the Juravinski Hospital. Healthcare Quarterly. 14:66-74. 2011
- An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.. Journal of Clinical Oncology. 29:7018-7018. 2011
- Selecting Patients with Extensive-Stage Small Cell Lung Cancer for Prophylactic Cranial Irradiation by Predicting Brain Metastases. Journal of Thoracic Oncology. 6:808-812. 2011
- Advances in Cancer Therapeutics and Patient Access to New Drugs. PharmacoEconomics (Auckland). 29:213-224. 2011
- Multidisciplinary Health Care Professionals' Perceptions of the Use and Utility of a Symptom Assessment System for Oncology Patients. JCO Oncology Practice. 7:19-23. 2011
- Positron Emission Tomography with 18Fluorodeoxyglucose in Radiation Treatment Planning for Non-small Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology. 6:86-97. 2011
- The National Lung Screening Trial: Overview and Study Design. Radiology. 258:243-253. 2011
- Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs. Journal of Clinical Oncology. 28:4149-4153. 2010
- Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III Trial. Journal of the National Cancer Institute. 102:859-865. 2010
- Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer. Journal of the National Cancer Institute. 102:298-306. 2010
- First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology. 5:260-274. 2010
- Cancer Diagnostic Assessment Programs: Standards for the Organization of Care in Ontario. Current Oncology. 16:29-41. 2009
- Evidence-Based Approach to the Introduction of Positron Emission Tomography in Ontario, Canada. Journal of Clinical Oncology. 27:5607-5613. 2009
- Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. Journal of the National Cancer Institute. 101:1182-1192. 2009
- Positron Emission Tomography Plus Computed Tomography for Staging Early Lung Cancer. ACP journal club. 151:I-I. 2009
- Positron Emission Tomography in Staging Early Lung Cancer. ACP journal club. 151:221-221. 2009
- The Management of Thymoma: A Systematic Review and Practice Guideline. Journal of Thoracic Oncology. 4:911-919. 2009
- Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document. Journal of Clinical Oncology. 27:e17572-e17572. 2009
- Impact of positron emission tomography (PET) in stage III non-small cell lung cancer (NSCLC): A prospective randomized trial (PET START). Journal of Clinical Oncology. 27:7548-7548. 2009
- Integration between primary care providers and the cancer system: Gaps and opportunities. Journal of Clinical Oncology. 27:6584-6584. 2009
- PET-CT compared to invasive mediastinal staging in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27:7575-7575. 2009
- Health technology assessment: A comprehensive framework for evidence-based recommendations in Ontario. International Journal of Technology Assessment in Health Care. 25:141-150. 2009
- The Utility of Publicly Reported Cancer Treatment Wait Time Information for Patients and Health Care Providers. Clinical Oncology. 21:218-225. 2009
- A prospective study of peri-diagnostic and surgical wait times for patients with presumptive colorectal, lung, or prostate cancer. British Journal of Cancer. 100:56-62. 2009
- Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.. Journal of Population Therapeutics and Clinical Pharmacology. 16:e273-e281. 2009
- A prospective economic analysis of cost-effectiveness of cetuximab for metastatic colorectal cancer patients from the NCIC CTG and AGITG CO.17 trial. Journal of Clinical Oncology. 26:6528-6528. 2008
- Should Cost of Care be Considered in a Clinical Practice Guideline?. Journal of the National Comprehensive Cancer Network : JNCCN. 6:224-226. 2008
- Nursing care for patients with non-small cell lung cancer receiving adjuvant chemotherapy: Evidence–based implications for practice. Canadian Oncology Nursing Journal. 18:1-5. 2008
- Soins infirmiers pour patients atteints du cancer du poumon non à petites cellules recevant une chimiothérapie adjuvante : implications pour la pratique fondée sur les données probantes. Canadian Oncology Nursing Journal. 18:1-6. 2008
- 18Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer: A Systematic Review. Journal of the National Cancer Institute. 99:1753-1767. 2007
- Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline. Journal of Clinical Oncology. 25:5506-5518. 2007
- Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline. JCO Oncology Practice. 3:332-335. 2007
- M20-01: The cost of care for patients with lung cancer. Journal of Thoracic Oncology. 2:S209-S210. 2007
- P1-096: 18Fluorodeoxyglucose Positron Emission Tomography in the diagnosis and staging of lung cancer: a systematic review and practitioner guideline in Ontario, Canada. Journal of Thoracic Oncology. 2:S588-S588. 2007
- P1-097: 18Fluorodeoxyglucose Positron Emission Tomography and co-registered computed tomography for radiation treatment planning in lung cancer: a systematic review. Journal of Thoracic Oncology. 2:S588-S589. 2007
- P1-117: The development of a practice guideline for the management of malignant thymoma through a formal consensus process.. Journal of Thoracic Oncology. 2:S597-S597. 2007
- P1-248: Lung cancer guideline development in ontario: impact on policy and practice. Journal of Thoracic Oncology. 2:S837-S837. 2007
- A 10-year history of lung cancer practice guideline development: Process, productivity and impact. Journal of Clinical Oncology. 25:17044-17044. 2007
- A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non- small cell lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303). Journal of Clinical Oncology. 25:7527-7527. 2007
- Determining knowledge transfer gaps in the life cycle of evidence for chemotherapy in non-small cell lung cancer (NSCLC) through cumulative meta-analysis. Journal of Clinical Oncology. 25:6555-6555. 2007
- Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 25:2256-2261. 2007
- Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline. Journal of Thoracic Oncology. 2:348-354. 2007
- Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. Journal of Thoracic Oncology. 1:1042-1058. 2006
- The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline. Journal of Thoracic Oncology. 1:591-601. 2006
- The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non–small-cell lung cancer: A systematic review. Brachytherapy. 5:189-202. 2006
- The role of radiation therapy in malignant pleural mesothelioma: A systematic review. Radiotherapy and Oncology. 80:13-18. 2006
- Diagnostic assessment of suspected cancer: Prospective cohort study of diagnostic delay intervals across three disease sites. Journal of Clinical Oncology. 24:6029-6029. 2006
- Who are the users of publicly reported cancer treatment wait times (WT)?. Journal of Clinical Oncology. 24:6043-6043. 2006
- Adjuvant chemotherapy for completely resected non-small cell lung cancer: A systematic review. Critical Reviews in Oncology/Hematology. 58:146-155. 2006
- Management of unresected stage III non-small cell lung cancer: a systematic review.. Journal of Thoracic Oncology. 1:377-393. 2006
- Postoperative Chemotherapy in Nonsmall Cell Lung Cancer: A Systematic Review. Annals of Thoracic Surgery. 81:1926-1936. 2006
- Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.. Journal of Thoracic Oncology. 1:367-376. 2006
- Practitioner feedback on lung cancer practice guidelines in Ontario.. Journal of Thoracic Oncology. 1:10-18. 2006
- Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline. Lung Cancer. 50:355-374. 2005
- Diagnostic Imaging in Canada. Healthcare Papers. 6:8-15. 2005
- The Authors Respond. Healthcare Papers. 6:42-48. 2005
- The impact of practice guidelines and funding policies on the use of new drugs in advanced non‐small cell lung cancer*. Journal of Evaluation in Clinical Practice. 11:350-356. 2005
- PD-118 High dose rate endobronchial brachytherapy (HDREB) in the palliation of patients with non-small cell lung cancer (NSCLC): A systematic review. Lung Cancer. 49:S101-S102. 2005
- A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303): An interim report of toxicity and response. Journal of Clinical Oncology. 23:7144-7144. 2005
- Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta analysis of the literature. Journal of Clinical Oncology. 23:6082-6082. 2005
- Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer. 48:157-169. 2005
- Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung Cancer. Journal of Clinical Oncology. 23:850-856. 2005
- Job stress and job satisfaction of cancer care workers. Psycho-Oncology. 14:61-69. 2005
- Adjuvant chemotherapy with uracil-tegafur prolongs overall survival in people with primary adenocarcinoma of the lung. Cancer Treatment Reviews. 30:661-664. 2004
- Adjuvant chemotherapy with uracil–tegafur prolongs overall survival in people with primary adenocarcinoma of the lung☆☆☆☆☆☆Abstracted from: Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil–tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713–21.. Cancer Treatment Reviews. 30:661-664. 2004
- Gefitinib does not improve survival when combined with gemcitabine and cisplatin in people with advanced non-small-cell lung cancer☆☆☆☆☆☆Abstracted from: Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777–784.. Cancer Treatment Reviews. 30:651-653. 2004
- Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆☆☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.. Cancer Treatment Reviews. 30:655-659. 2004
- Practitioner feedback on clinical practice guidelines developed by Cancer Care Ontario's Lung Disease Site Group: Extending the circle of involvement. Journal of Clinical Oncology. 22:6031-6031. 2004
- Practitioner feedback on clinical practice guidelines developed by Cancer Care Ontario's Lung Disease Site Group: Extending the circle of involvement. Journal of Clinical Oncology. 22:6031-6031. 2004
- Better Knowledge Translation for Effective Cancer Control: A Priority for Action. Cancer Causes and Control. 15:503-510. 2004
- Photodynamic therapy in nonsmall cell lung cancer: a systematic review. Annals of Thoracic Surgery. 77:1484-1491. 2004
- Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer. 44:1-11. 2004
- Treatment of recurrent small cell lung cancer. Hematology/Oncology Clinics of North America. 18:387-416. 2004
- Evaluation of Diagnostic Assessment Units in Oncology: A Systematic Review. Journal of Clinical Oncology. 22:1126-1135. 2004
- Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer. 43:223-240. 2004
- The role of knowledge translation for cancer control in Canada.. Chronic Diseases and Injuries in Canada. 25:1-6. 2004
- O-189 Practitioner feedback on lung cancer practice guidelines developed through cancer care Ontario's program in evidence-based care. Lung Cancer. 41:S56-S56. 2003
- O-193 The impact of practice guidelines and funding policies on the utilization and cost of chemotherapy in advanced non-small cell lung cancer (NSCLC): The experience from the province of Ontario, Canada. Lung Cancer. 41:S57-S57. 2003
- O-311 A phase III study of Æ-941 (Neovastat®) with induction chemotherapy (IC) and conconmitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim analysis of toxicity and response. Lung Cancer. 41:S90-S90. 2003
- Lifetime costs of colon and rectal cancer management in Canada.. Chronic Diseases and Injuries in Canada. 24:91-101. 2003
- Phase I/II Trial of the Safety and Efficacy of AE-941 (Neovastat®) in the Treatment of Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 4:231-236. 2003
- Use of gemcitabine in non-small-cell lung cancer. Current Oncology. 10:3-26. 2003
- Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis.. Chronic Diseases and Injuries in Canada. 24:102-107. 2003
- Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer. Current Opinion in Oncology. 14:375-383. 2002
- The cost and cost-effectiveness of treating non-small-cell lung cancer. Oncology Spectrums. 3:35-41. 2002
- Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.. Chronic Diseases and Injuries in Canada. 23:152-156. 2002
- Epoetin Alfa in Cancer Patients. Journal of Pain and Symptom Management. 22:954-965. 2001
- First do no harm: extending the debate on the provision of preventive tamoxifen. British Journal of Cancer. 85:1280-1288. 2001
- Canada's Population Health Model (POHEM). European Journal of Cancer. 37:1797-1804. 2001
- Funding New Cancer Drugs in Ontario: Closing the Loop in the Practice Guidelines Development Cycle. Journal of Clinical Oncology. 19:3392-3396. 2001
- Practice guideline on prophylactic cranial irradiation in small-cell lung cancer. International Journal of Radiation Oncology Biology Physics. 50:309-316. 2001
- Structured Exercise Improves Physical Functioning in Women With Stages I and II Breast Cancer: Results of a Randomized Controlled Trial. Journal of Clinical Oncology. 19:657-665. 2001
- The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer. Current Oncology. 8:50-59. 2001
- BREAST CANCER: BETTER CARE FOR LESS COST Is It Possible?. International Journal of Technology Assessment in Health Care. 16:1168-1178. 2000
- Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute. 92:1321-1329. 2000
- Cancer care workers in Ontario: prevalence of burnout, job stress and job satisfaction.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 163:166-169. 2000
- Development and evaluation of a decision aid for patients with stage IV non‐small cell lung cancer. Health Expectations. 3:125-136. 2000
- An estimate of the cost of conducting phase II trials in lung cancer. Lung Cancer. 28:85-95. 2000
- Estimates of the lifetime costs of breast cancer treatment in Canada. European Journal of Cancer. 36:724-735. 2000
- Cost-effectiveness analysis in oncology.. Praxis. 89:492-496. 2000
- Clinical Characteristics and the Impact of Surgery and Chemotherapy on Survival of Patients With Advanced and Metastatic Bronchioloalveolar Carcinoma: A Retrospective Study. Clinical Lung Cancer. 1:211-215. 2000
- Altered fractionation of radical radiaton therapy in the management of unresectable non-small-cell lung cancer. Current Oncology. 7:98-109. 2000
- Canadian Oncologists and Clinical Practice Guidelines: A National Survey of Attitudes and Reported Use. Oncology. 59:283-290. 2000
- The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small-cell lung cancer. Current Oncology. 7:162-172. 2000
- New insights into the cost-effectiveness of lung cancer treatment. Oncology. 13:16-21. 1999
- Commentary on “The Benefit of Support Group Participation to Lung Cancer Survivors”. Clinical Lung Cancer. 1:118-118. 1999
- The cost of radiotherapy at an Ontario regional cancer centre: a re-evaluation. Critical Reviews in Oncology/Hematology. 32:87-93. 1999
- Concurrent use of multiple low dose chemotherapy agents with differing mechanisms of action as a strategy vs passive resistance: A pilot study.. International Journal of Oncology. 15:693-699. 1999
- Æ-941, an inhibitor of angiogenesis: rationale for development in combination with induction chemotherapy/radiotherapy in patients with non-small-cell lung cancer (nsclc). European Journal of Cancer. 35:S250-S250. 1999
- Oncology Rehabilitation Program at the Ottawa Regional Cancer Centre: program description.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 161:282-285. 1999
- Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. British Journal of Cancer. 80:815-820. 1999
- Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs. British Journal of Cancer. 79:1428-1436. 1999
- The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.. Cancer Prevention and Control. 3:84-94. 1999
- Concurrent chemotherapy with hyperfractionated accelerated thoracic irradiation in stage III non-small cell lung cancer. Lung Cancer. 23:19-30. 1999
- Costs of Treating and Preventing Nausea and Vomiting in Patients Receiving Chemotherapy. Journal of Clinical Oncology. 17:344-344. 1999
- Decision Aids for Patients Considering Options Affecting Cancer Outcomes: Evidence of Efficacy and Policy Implications. Journal of the National Cancer Institute. Monographs. 1999:67-80. 1999
- A Comparison with Standard Chemotherapy and Best Supportive Care: Cost-Effectiveness of Vinorelbine Alone or Vinorelbine Plus Cisplatin for Stage IV NSCLC. Oncology. 12:18-25. 1998
- A phase I study of gemcitabine/cisplatin/etoposide in the treatment of small-cell lung cancer. Lung Cancer. 22:235-241. 1998
- Capturing tumour stage in a cancer information database.. Cancer Prevention and Control. 2:304-309. 1998
- The consultation to develop a national strategy for cancer staging in Canada.. Cancer Prevention and Control. 2:287-294. 1998
- How interested is the public in genetic testing for colon cancer susceptibility? Report of a cross-sectional population survey.. Cancer Prevention and Control. 2:167-172. 1998
- Cost-effectiveness analysis in oncology. Annals of Oncology. 9:475-482. 1998
- Follow-up practices for patients with early stage breast cancer: a survey of Canadian oncologists.. Cancer Prevention and Control. 2:63-71. 1998
- Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC. Oncology. 12:18-26. 1998
- Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.. Oncology. 12:18-25. 1998
- Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback.. Journal of Clinical Oncology. 16:1226-1231. 1998
- Combined modality therapy for lung cancer - Reply. Journal of Clinical Oncology. 16:808-808. 1998
- Combined modality therapy for lung cancer.. Journal of Clinical Oncology. 16:807-808. 1998
- Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.. Cancer Prevention and Control. 2:32-39. 1998
- Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.. Cancer Prevention and Control. 1:366-378. 1997
- PP15. Methods for conducting economic analysis of the long-term management of breast cancer: Description of two current Canadian studies. European Journal of Cancer. 33:S19-S20. 1997
- A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer.. Cancer Prevention and Control. 1:282-288. 1997
- Cost of combined modality interventions for stage III non-small-cell lung cancer.. Journal of Clinical Oncology. 15:3038-3048. 1997
- Lung cancer practice guidelines: lessons learned and issues addressed by the Ontario Lung Cancer Disease Site Group.. Journal of Clinical Oncology. 15:3049-3059. 1997
- 103 Multiple low dose chemotherapy agents for passive resistance in non-small cell lung cancer (NSCLC) and other malignancies. A pilot study. Lung Cancer. 18:29-29. 1997
- 168 A pilot study of high dose chemotherapy and irradiation with NEUPOGEN (G-CSF) in limited disease small cell lung cancer (SCLC). Lung Cancer. 18:45-45. 1997
- 182 High dose doxorubicin, cisplatin and tamoxifen vs mesothelioma. Lung Cancer. 18:49-49. 1997
- 183 Gemcitabine (G), VP16 (V) and cisplatin (P). Phase I study in small cell lung cancer (SCLC). Lung Cancer. 18:49-49. 1997
- 234 Importance of timing for thoracic irradiation (TI) in the combined modality treatment of limited-stage small-cell lung cancer (LSCLC): An update of the National Cancer Institute of Canada (NCIC) BR6 study. Lung Cancer. 18:61-61. 1997
- 90 Comparison of the costs, toxicities, and inconvenience of different chemotherapy regimens for advanced non-small cell lung cancer. Lung Cancer. 18:26-26. 1997
- Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer. Lung Cancer. 18:83-94. 1997
- Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.. Cancer Prevention and Control. 1:249-259. 1997
- Management Issues for Stage IV Non-Small-Cell Lung Cancer. Cancer Control. 4:307-316. 1997
- Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.. Seminars in Oncology. 24:S8-27-S8-30. 1997
- Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.. Journal of Clinical Oncology. 15:1897-1905. 1997
- Arterial occlusion in patients with peripheral vascular disease treated with platinum-based regimens for lung cancer. Cancer Chemotherapy and Pharmacology. 40:19-22. 1997
- Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: An estimate using the population health model lung cancer module. Seminars in Oncology. 24:S56-S63. 1997
- Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.. Cancer Prevention and Control. 1:18-27. 1997
- Use of vinorelbine in non-small-cell lung cancer. Provincial Lung Disease Site Group.. Cancer Prevention and Control. 1:28-38. 1997
- The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. European Journal of Cancer. 32:2249-2255. 1996
- An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer. Seminars in Oncology. 23:82-89. 1996
- An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer.. Seminars in Oncology. 23:82-89. 1996
- Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer. Lung Cancer. 15:115-123. 1996
- The economics of lung cancer management in Canada. Lung Cancer. 14:19-29. 1996
- Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.. The Canadian journal of oncology. 5:408-419. 1995
- 1057 The health economics of lung cancer and an estimate of the cost effectiveness of single agent gemcitabine in stage IV NSCLC. European Journal of Cancer. 31:S221-S221. 1995
- 1100 Concurrent daily chemotherapy with hyperfractionated thoracic irradiation in stage IIIA & B NSCLC. European Journal of Cancer. 31:S229-S229. 1995
- Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. British Journal of Cancer. 72:1270-1277. 1995
- The cost of managing lung cancer in Canada.. Oncology. 9:147-153. 1995
- Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Annals of Thoracic Surgery. 60:615-623. 1995
- A Phase II Study of 5-Fluorouracil Plus High-Dose Folinic Acid in the Treatment of Recurrent Small Cell Lung Cancer. American Journal of Clinical Oncology. 18:130-132. 1995
- Adjuvant chemotherapy: results and perspectives. Lung Cancer. 12:S35-S45. 1995
- Oral Etoposide and Carboplatin. American Journal of Clinical Oncology. 18:149-155. 1995
- High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: report of four cases. Lung Cancer. 11:251-258. 1994
- Addition of Pentoxifylline plus Nifedipine to Chemotherapy in Patients with Cisplatin-Resistant Cancers of the Lung and Other Sites. American Journal of Clinical Oncology. 17:313-316. 1994
- Duration of intravenous antibiotics for patients with neutropenic fever. Annals of Oncology. 5:441-445. 1994
- Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. International Journal of Radiation Oncology Biology Physics. 28:355-362. 1994
- Treatment of Small Cell Lung Cancer in the Elderly. Journal of The American Geriatrics Society. 42:64-70. 1994
- VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer. European Journal of Cancer. 30:299-303. 1994
- The role of chemotherapy in invasive thymoma: a review of the literature and considerations for future clinical trials. Critical Reviews in Oncology/Hematology. 15:113-124. 1993
- Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group.. Journal of Clinical Oncology. 11:1592-1597. 1993
- Rationale for the treatment of non-small cell lung cancer. Lung Cancer. 9:5-14. 1993
- Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 11:336-344. 1993
- A model for estimating the costs and burdens of breast cancer diagnosis and treatment in Canada.. Health Reports. 5:399-408. 1993
- Management of Metastatic Non-Small-Cell Lung Cancer and a Consideration of Cost. Chest. 103:68S-71S. 1993
- Management of metastatic non-small-cell lung cancer and a consideration of cost. Chest. 103:68S-71. 1993
- Phase II study of lonidamine plus radiotherapy in the treatment of brain metastases. Journal of Neuro-Oncology. 15:19-22. 1993
- A PHASE-II STUDY OF IFOSFAMIDE IN COMBINATION WITH ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF EXTENSIVE SMALL-CELL LUNG-CANCER. Seminars in Oncology. 19:51-57. 1992
- A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.. Seminars in Oncology. 19:51-56. 1992
- Second primary malignancies following diagnosis of small-cell lung cancer.. Journal of Clinical Oncology. 10:1525-1533. 1992
- Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.. Seminars in Oncology. 19:54-58. 1992
- Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 10:297-303. 1992
- Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer.. Journal of Clinical Oncology. 10:21-27. 1992
- Small-cell carcinoma of the lung: derivation of a prognostic staging system.. Journal of Clinical Oncology. 9:1639-1649. 1991
- The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer.. Journal of Clinical Oncology. 9:954-961. 1991
- Surgical treatment for limited small-cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 101:385-393. 1991
- The effect of lonidamine alone and in combination with cisplatin on in vitro growth and viability of lung squamous cell carcinoma cell lines.. Anticancer Research. 11:41-47. 1991
- The in vitro effects of lonidamine combined with cisplatin in human small cell lung cancer cell lines.. Anticancer Research. 11:235-239. 1991
- Phase I Study of Acivicin and Cisplatin in Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology. 13:401-404. 1990
- A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report.. Seminars in Oncology. 17:19-23. 1990
- Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.. Journal of Clinical Oncology. 8:390-395. 1990
- Late neurological complications after prophylactic cranial irradiation in patients with small-cell lung cancer: the Toronto experience.. Journal of Clinical Oncology. 8:215-221. 1990
- 5-Fluorouracil with Folinic Acid is Not Effective Against Metastatic Adenocarcinoma of the Lung. Cancer Investigation. 8:345-349. 1990
- Supportive care for patients with small cell lung cancer. Lung Cancer. 5:319-324. 1989
- The role of thoracic radiation therapy in small cell carcinoma of the lung: a concensus report. Lung Cancer. 5:135-138. 1989
- Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.. Journal of Clinical Oncology. 7:1157-1168. 1989
- ADJUVANT THERAPY FOR NON-SMALL CELL LUNG-CANCER. Chest. 96:S87-S91. 1989
- Adjuvant therapy for non-small cell lung cancer.. Chest. 96:87S-91S. 1989
- Non-chemotherapeutic agents that potentiate chemotherapy efficacy. Cancer Treatment Reviews. 16:1-40. 1989
- A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 97:177-186. 1989
- Carcinoembryonic Antigen, Arginine Vasopressin and Calcitonin as Markers of Early Small-Cell Lung Cancer Relapse. Tumor Biology. 10:258-267. 1989
- A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. Investigational New Drugs. 6:327-329. 1988
- COMBINATION CHEMOTHERAPY CONFERS MODEST SURVIVAL ADVANTAGE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG-CANCER - REPORT OF A CANADIAN MULTICENTER RANDOMIZED TRIAL. Seminars in Oncology. 15:42-45. 1988
- Combination chemotherapy confers modest survival advantage in patients with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trial.. Seminars in Oncology. 15:42-45. 1988
- Resting energy expenditure in lung and colon cancer. Metabolism: Clinical and Experimental. 37:1059-1064. 1988
- Combination chemotherapy and alpha-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 139:635-639. 1988
- Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer.. Journal of Clinical Oncology. 6:1537-1547. 1988
- VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. British Journal of Cancer. 58:464-468. 1988
- Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung.. Journal of Clinical Oncology. 6:832-838. 1988
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.. Journal of Clinical Oncology. 6:633-641. 1988
- Correction: Omitted Author's Name. ACP journal club. 108:496-496. 1988
- Chemotherapy following surgery for stages IE and IIE non-Hodgkin's lymphoma of the gastrointestinal tract.. Journal of Clinical Oncology. 6:253-260. 1988
- The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a canadian multicenter randomized trial. International Journal of Radiation Oncology Biology Physics. 14:219-226. 1988
- Medical management of malignant pericardial effusion by tetracycline sclerosis. American Journal of Cardiology. 60:1161-1166. 1987
- Neurologic disorders in patients with small cell lung cancer. Cancer. 60:2275-2283. 1987
- Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.. Journal of the National Cancer Institute. 71:941-944. 1987
- Superiority of Alternating Non-Cross-Resistant Chemotherapy in Extensive Small Cell Lung Cancer. ACP journal club. 107:451-451. 1987
- Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.. Journal of Clinical Oncology. 5:1401-1409. 1987
- Intra-Arterial Cisplatin for Bladder Cancer. Investigative Urology. 138:302-305. 1987
- Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma.. Journal of Clinical Oncology. 5:635-640. 1987
- A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer.. Journal of Clinical Oncology. 5:113-124. 1987
- Nystatin lozenges: A useful treatment for oral candidiasis in cancer patients. Current Therapeutic Research - Clinical and Experimental. 42:1201-1209. 1987
- Canadian multicentre randomized trial comparing two dose levels of thoracic radiation given in combination with chemotherapy to patients with limited small cell lung cancer. International Journal of Radiation Oncology Biology Physics. 12:157-157. 1986
- 5-Fluorouracil, Adriamycin, and Mitomycin-C (FAM) in the Treatment of Inoperable Adenocarcinoma of the Lung. American Journal of Clinical Oncology. 9:392-396. 1986
- Is Bone Marrow Examination in Small-Cell Lung Cancer Really Necessary?. ACP journal club. 105:508-508. 1986
- 1ST-LINE THERAPY WITH VP-16 AND CISPLATIN FOR SMALL-CELL LUNG-CANCER. Seminars in Oncology. 13:17-23. 1986
- Combined chemotherapy and radiation therapy for non-small-cell lung cancer.. Seminars in Oncology. 13:121-124. 1986
- First-line therapy with VP-16 and cisplatin for small-cell lung cancer.. Seminars in Oncology. 13:17-23. 1986
- The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.. Seminars in Oncology. 13:10-16. 1986
- Therapy-Related Leukemia and Myelodysplasia in Small-cell Lung Cancer. JAMA Internal Medicine. 146:1689-1689. 1986
- Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study.. Journal of the National Cancer Institute. 70:1029-1030. 1986
- Superior vena caval obstruction syndrome in small cell lung cancer. Cancer. 57:847-851. 1986
- Methyl-CCNU and Methotrexate Therapy in Patients with Advanced Colorectal Cancer After Failure of 5-Fluorouracil Chemotherapy. American Journal of Clinical Oncology. 9:27-30. 1986
- Tetracycline sclerosis in the management of malignant pericardial effusion.. Journal of Clinical Oncology. 3:1678-1682. 1985
- Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.. Journal of Clinical Oncology. 3:1478-1485. 1985
- VP-16 and cisplatin as first-line therapy for small-cell lung cancer.. Journal of Clinical Oncology. 3:1471-1477. 1985
- Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer.. Journal of Clinical Oncology. 3:1349-1354. 1985
- Short course prophylactic cranial irradiation for small cell lung cancer. American Journal of Clinical Oncology. 8:371-376. 1985
- Elevated Levels of Interferon-Induced 2'-5' Oligoadenylate Synthetase in Generalized Persistent Lymphadenopathy and the Acquired Immunodeficiency Syndrome. Journal of Infectious Diseases. 152:466-472. 1985
- Effects of intravenous hyperalimentation during treatment in patients with small-cell lung cancer.. Journal of Clinical Oncology. 3:949-957. 1985
- Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer.. Cancer Research. 45:3347-3353. 1985
- Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.. Journal of the National Cancer Institute. 69:727-728. 1985
- Ketoconazole. Use in the treatment of ectopic adrenocorticotropic hormone production and Cushing's syndrome in small-cell lung cancer. JAMA Internal Medicine. 145:863-864. 1985
- The effect of intravenous hyperalimentation on the dietary intake of patients with small cell lung cancer. A randomized trial. Cancer. 55:1572-1578. 1985
- Effect of adjuvant central iv hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: a randomized trial.. Journal of the National Cancer Institute. 69:167-177. 1985
- Failure of 5-day vinblastine infusion in the treatment of patients with renal cell carcinoma.. Journal of the National Cancer Institute. 69:227-228. 1985
- Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.. Journal of the National Cancer Institute. 69:209-210. 1985
- CORRECTION. Journal of Clinical Oncology. 3:1045-1045. 1985
- Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.. Journal of Clinical Oncology. 3:65-71. 1985
- Changes in Body Composition in Patients with Small-Cell Lung Cancer. ACP journal club. 101:303-303. 1984
- Myasthenic syndrome and small cell cancer of the lung. Variable response to antineoplastic therapy.. JAMA Internal Medicine. 144:999-1000. 1984
- Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer. 53:1667-1674. 1984
- Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung.. Journal of Clinical Oncology. 2:294-304. 1984
- Effects of total parenteral nutrition and chemotherapy on the metabolic derangements in small cell lung cancer.. Cancer Research. 44:1706-1711. 1984
- VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer. 53:1461-1466. 1984
- Acute lymphoblastic leukemia possible origin from a mediastinal germ cell tumor. Cancer. 53:441-444. 1984
- Cytologic diagnosis of hepatocellular carcinoma by fine-needle aspiration biopsy. Cancer. 53:547-552. 1984
- Serum folate and vitamin B12 levels in patients with small cell lung cancer. Cancer. 53:306-310. 1984
- Phase II Evaluation of Lonidamine in Patients with Advanced Malignancy. Oncology. 41:69-77. 1984
- Reduction in local recurrence and improved survival in surgically treated patients with small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 86:498-506. 1983
- Upper half body irradiation (UHBI) for extensive small cell carcinoma of the lung. International Journal of Radiation Oncology Biology Physics. 9:1571-1574. 1983
- Intramedullary spinal cord metastases from small cell carcinoma of the lung.. Journal of Clinical Oncology. 1:99-106. 1983
- Chemotherapy for metastatic transitional carcinoma of the urinary tract:A prospective trial of methotrexate, adriamycin, and cyclophosphamide (MAC) with cis-platinum for failure. Cancer. 51:216-219. 1983
- Herpes zoster in patients with carcinoma of the lung. American Journal of Medicine. 73:795-801. 1982
- Tumours of the mononuclear phagocyte system: A review of clinical and pathological features. American Journal of Hematology. 13:171-184. 1982
- Dr. Evans and colleagues comment. Radiology. 143:573-574. 1982
- COMPUTED-TOMOGRAPHY OF THE BRAIN, LIVER, AND UPPER ABDOMEN IN THE STAGING OF SMALL CELL-CARCINOMA OF THE LUNG. Journal of Computer Assisted Tomography. 6:963-965. 1982
- Avascular necrosis of bone complicating treatment of malignant lymphoma. American Journal of Medicine. 71:751-758. 1981
- Fatal necrotizing pancreatitis following fine-needle aspiration biopsy of the pancreas.. Radiology. 141:61-62. 1981
- Upper half body irradiation (uhbi) for extensive small cell carcinoma of lung (SCCL). International Journal of Radiation Oncology Biology Physics. 7:1263-1263. 1981
- Guided percutaneous fine-needle aspiration biopsy of the liver. Cancer. 47:1781-1785. 1981
- Combined Modality Treatment of Small Cell Carcinoma of the Lung. JAMA Internal Medicine. 141:469-469. 1981
- Combined modality treatment of small cell carcinoma of the lung. JAMA Internal Medicine. 141:469-473. 1981
- Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma.. Journal of the National Cancer Institute. 65:947-954. 1981
- METHOTREXATE, ADRIAMYCIN AND CYCLOPHOSPHAMIDE (MAC) CHEMOTHERAPY FOR TRANSITIONAL CELL-CARCINOMA OF THE URINARY-TRACT. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 22:461-461. 1981
- Nutritional status of patients with lung carcinoma: The effect of chemotherapy and parenteral nutrition. Clinical and Investigative Medicine. 4. 1981
- VP-16 AND CIS-PLATINUM (P) COMBINATION CHEMOTHERAPY FOR RELAPSE IN SMALL CELL LUNG-CANCER (SCLC). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 22:495-495. 1981
- VP-16 and cis-platinum (P) combination chemotherapy for relapse in small cell lung cancer (SCLC). Annals of the Royal College of Physicians and Surgeons of Canada. 14. 1981
- Combination chemotherapy in invasive thymoma role of COPP.. Cancer. 46:1523-1527. 1980
- Herpes Zoster in Patients with Small-Cell Carcinoma of the Lung Receiving Combined Modality Treatment. ACP journal club. 93:282-282. 1980
- Reversal of hypertrophic osteoarthropathy after chemotherapy for bronchogenic carcinoma.. Journal of Rheumatology. 7:93-97. 1980
- A study of chemotherapy + non-specific immunostimulation for colo-rectal and gastric cancer. Annals of the Royal College of Physicians and Surgeons of Canada. 12. 1979
- THE INVITRO EFFECTS OF LONIDAMINE COMBINED WITH CISPLATIN IN HUMAN SMALL-CELL LUNG-CANCER CELL-LINES. Anticancer Research. 11:235-239.
-
other
- PERUGIA INTERNATIONAL CANCER CONFERENCE .1. DISCUSSION. Seminars in Oncology. 62-70. 1988
-
preprints